Blossom Pharmaceuticals Initiates Nationwide Recall of Zinc Oxide Ointment Over cGMP Deviations
Blossom Pharmaceuticals has initiated a voluntary Class II recall of 33,000 containers of Globe Zinc Oxide Ointment USP 20% due to cGMP deviations at its Bardej, Goa, India facility. This action, impacting USA nationwide distribution by Trifecta Pharmaceuticals USA, signals critical supply chain vulnerabilities and heightened regulatory scrutiny for procurement and regulatory affairs teams managing topical OTC drug portfolios.
FDA-Mandated Recall: Blossom Pharmaceuticals' cGMP Deviations for Zinc Oxide Ointment
Blossom Pharmaceuticals, based in Bardej, Goa, India, has initiated a Class II voluntary recall (D-0212-2026) for 33,000 containers of its Globe Zinc Oxide Ointment USP Zinc Oxide 20% Skin Protectant. This significant action, reported on December 10, 2025, stems directly from identified deviations from current Good Manufacturing Practices (cGMP) at the company's manufacturing facility. The affected product, a human OTC drug administered topically, was distributed nationwide across the USA by Trifecta Pharmaceuticals USA. Specifically, the recall targets Lot #: A502404 (Exp. Date 2/27), A502405 (Exp. Date 2/27), and AS02502 (Exp. Date 2/28), identifiable by NDC 69396-086-02. For procurement directors, this event necessitates an immediate review of inventory and supply agreements for ZINC OXIDE 20% products, particularly those originating from Blossom Pharmaceuticals. The cGMP deviations indicate systemic quality control issues that could impact product efficacy and safety, demanding a proactive assessment of all related product lines and potential regulatory exposure for your organization.
Facility Profile: Blossom Pharmaceuticals' Indian Manufacturing Footprint and Key Products
The recalled Globe Zinc Oxide Ointment USP Zinc Oxide 20% originates from Blossom Pharmaceuticals' facility located at Plot No. 21/22, Karaswada-Tivim, Bardej, Goa, India. This facility is a key supplier for the US market, manufacturing ZINC OXIDE 20%, a widely used topical skin protectant. While specific production capacity figures or an FEI number for this site are not publicly available in the immediate context, the recall of 33,000 containers underscores its role in the supply chain for this over-the-counter (OTC) medication. The distribution of this product across the USA by Trifecta Pharmaceuticals USA highlights the facility's reach into a critical global market. For business development executives and supply chain VPs, this event signals potential vulnerabilities in sourcing strategies reliant on single facilities, particularly those in geographies facing increasing regulatory scrutiny. Understanding the full scope of products manufactured at this Bardej, Goa site and their respective market destinations is crucial for assessing broader supply chain risks and potential future disruptions.
Supply Chain Exposure: Immediate Impact on US Zinc Oxide Procurement
The recall of 33,000 containers of Globe Zinc Oxide Ointment USP Zinc Oxide 20% presents an immediate and tangible supply chain disruption for US-based distributors and formulators. Trifecta Pharmaceuticals USA, located at 101 NE, Third Avenue, Suite 1500, Ft. Lauderdale, FL 33301, is identified as the distributor for this product across the USA. Procurement teams must promptly identify if their current inventory or future orders include the affected lots (A502404, A502405, AS02502) or any other products from Blossom Pharmaceuticals' Bardej, Goa facility. The nationwide distribution pattern means the impact is not geographically isolated within the US, requiring a broad assessment of stock levels and potential backorders. Regulatory affairs heads must also consider the implications for product registration and compliance, as sourcing from a facility with cGMP deviations can trigger enhanced scrutiny from the FDA on downstream products. This situation mandates rapid communication with suppliers and a comprehensive review of quality agreements to ensure continuity of supply and regulatory adherence.
Alternative Sourcing Strategies for Topical Zinc Oxide API and Formulations
Given the ongoing recall by Blossom Pharmaceuticals due to cGMP deviations, procurement directors must immediately explore and qualify alternative suppliers for ZINC OXIDE 20% and its related formulations. While specific alternative suppliers are not detailed in the available intelligence, a robust strategy involves diversifying sourcing geographically to mitigate single-point-of-failure risks. Companies should consider established manufacturers in regions with stringent regulatory oversight, such as North America, Europe, or other well-audited Asian facilities. The qualification process for a new pharmaceutical supplier, including site audits, analytical testing, and regulatory documentation, can span 6 to 18 months, emphasizing the urgency of initiating this process now. Business development executives should also assess their product portfolios for reliance on ZINC OXIDE 20% from potentially compromised sources, identifying opportunities to partner with more resilient supply chains. Proactive engagement with multiple qualified suppliers is critical to safeguard against future disruptions and maintain market supply for essential OTC products.
Blossom Pharmaceuticals' Regulatory Compliance History and Future Scrutiny
The current Class II recall marks a significant regulatory event for Blossom Pharmaceuticals. While no prior FDA Warning Letters, 483s, or Import Alerts for Blossom Pharmaceuticals are detailed in the available knowledge graph, this firm-initiated recall due to cGMP deviations indicates a critical lapse in their quality management systems. Such an event typically triggers heightened scrutiny from the FDA, potentially leading to future inspections and more stringent oversight of all products originating from their Bardej, Goa facility. Regulatory affairs heads should anticipate increased due diligence requirements for any products sourced from Blossom Pharmaceuticals. The FDA's consistent focus on cGMP compliance, as evidenced by recent parallel events like Essential Wellness Pharma's recall for sterility assurance failures, underscores a broader trend of rigorous enforcement, particularly for imported drugs. This recall serves as a clear signal that companies must re-evaluate their risk profiles for all suppliers, especially those with emerging compliance issues, to avoid downstream regulatory and reputational damage.
Remediation Pathways and Projected Regulatory Actions for Blossom Pharmaceuticals
The recall status for Blossom Pharmaceuticals' Globe Zinc Oxide Ointment USP Zinc Oxide 20% is currently 'Ongoing,' indicating that the company is in the process of addressing the cGMP deviations and managing the product retrieval. Blossom Pharmaceuticals is now obligated to conduct a thorough root cause analysis of the cGMP failures and implement comprehensive corrective and preventive actions (CAPA). The FDA will closely monitor the effectiveness of these remediation efforts. Failure to adequately resolve the identified cGMP deviations could escalate regulatory actions, potentially including an FDA Warning Letter, placement on an Import Alert for the Bardej, Goa facility, or even further product withdrawals. An Import Alert would effectively halt all future shipments from the affected facility into the USA, creating severe and long-lasting supply disruptions. Supply chain VPs and regulatory affairs heads should prepare for potential extended interruptions from this supplier and proactively engage with Blossom Pharmaceuticals to understand their remediation timeline and ensure robust oversight of their corrective measures to mitigate future risks.